ORDER A TEST Log In Contact Us

NEWS

Press Releases

Media Coverage

Additional Partnerships

Filter By
  • 11/20/2024

    University of Washington

    Researchers at Tempus partnered with the University of Washington to study the genomic alteration (GA) landscape of pure urothelial (UC) and histologic subtypes of bladder cancer. This analysis promises to yield insight into variant histology bladder cancers to better understand their lack of clinical response, and potentially identify modes of therapeutic intervention. This study was presented at the ASCO GU Cancers S...

  • 10/10/2024

    OneOncology

    Tempus is collaborating with OneOncology, the fastest-growing national platform for independent oncology practices, to broaden patient access to cutting-edge clinical trials. As part of the collaboration, Tempus is combining the power of its TIME Trial® Program with OneOncology’s robust research infrastructure and large national network of oncology...

  • 10/10/2024

    Washington University

    Researchers from Tempus partnered with Washington University School of Medicine to study the association between germline alterations in cancer-predisposition genes across lung cancer patients.   Historically, the understanding of the molecular features of lung cancer has been derived primarily from a limited approach focussed on analysis of biopsies from smokers. Few studies have identified the underlying genetic alterations linked to ancest...

  • 09/11/2024

    Henry Ford Health

    Researchers at Tempus partnered with Henry Ford Health to study and identify the key molecular differences between Black and African American and White patients’ pancreatic tumors.  Certain molecular tumor characteristics occur more frequently in Black & African American (BAA) PDAC tumors. Alterations in genes such as KMT2C, more frequent in our cohort of BAA tumors, are known contributors to pancreatic tumorigenesis and represent potential therapeutic targets. Fin...

  • 08/12/2024

    University of Minnesota

    Researchers from Tempus partnered with the University of Minnesota to study how gHRR alterations may influence somatic mutational landscapes in BRCA-associated cancers. The underlying genetic background underpinning prostate cancer has the potential to influence mutations that occur in the tumor during progression of the disease. This project looks at a specific group of patients that have genetic germline mutations in ATM, BRCA2, CHEK2, and PALB2 in order to determine...

  • 07/18/2024

    Mayo Clinic

    Researchers from Tempus partnered with Mayo Clinic to study individuals with breast cancer subjected to Tempus xT tumor-normal matched sequencing. Most studies of hereditary breast cancer have focused only a small-subset of patients with an aggressive disease known as Triple Negative Breast Cancer. This study seeks to improve our understanding of all breast cancer patients by exploring the molecular features of their tumors to identify hereditary mutations, and other features that will uncover pot...

  • 10/04/2023

    Stanford University

    Researchers from Tempus partnered with Stanford University to study the genomic landscape and immunotherapy biomarkers of metastatic renal cell carcinoma (RCC) patients with and without pancreatic metastases. Pancreatic metastases in RCC have been associated with features associated with worse response to immunotherapy. This study compared the genomic landscape and immunotherapy biomarkers of metastatic RCC patients with and without pancreatic metastases. The study found that RCC patients with pan...

  • 06/26/2023

    Roswell Park Comprehensive Cancer Center

    Researchers from Tempus partnered with the Roswell Park Comprehensive Cancer Center to study aberrations in patients with metastatic non-small cell lung cancer.  FGFR fusions represent a potential mechanism of resistance to EGFR inhibitors. This study characterizes the prevalence of these alterations and the landscape of co-mutations that may be of high interest to drug developers targeting FGFR fusions. This study was presented at the Targeted Therapies of Lung Cancer Meeting in February 2023...

  • 06/08/2023

    UCLA Mattel Children’s Hospital

    Researchers from Tempus have partnered with the UCLA Mattel Children's Hospital to expand the TIME Trial Program and help pediatric patients access clinical trials. With the addition of UCLA, TIME will expand trial access to pediatric and adolescent/young adult (AYA) patients for the first time. Dr. Noah Federman, the Nancy and Jonat...

  • 04/19/2023

    Northwestern University, Baylor University, Cedar Sinai & University of Pittsburgh

    Researchers from Tempus studied the mutational landscape of patients with metastatic breast cancer. Partners in the study included: Northwestern University's Robert H. Lurie Comprehensive Cancer Center; Baylor University's Dan L. Duncan Comprehensive Cancer Center; Cedar Sinai’s Samuel Oschin Comprehensive Cancer Center; and University of Pittsburgh’s Hillman Cancer Center. CDK4/6 inhibitors (CDK4/6i), such as palbociclib, ribociclib, and abemaciclib, in combination with antiestro...

1 2